Arrowhead Pharmaceuticals, Inc. (NASDAQ ... in this deal soaks up current excess manufacturing capacity in our new Verona manufacturing plant and to defrayes our operating costs.
Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback